Hemophagocytic Lymphohistiocytosis Associated With Parvovirus B19 in a Patient With Acquired Immunodeficiency Syndrome
Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by widespread inflammation due to massive immune activation and cytokine release. It is of 2 types, primary or familial and secondary or acquired. Diagnosis is made by fulfilling 5 of 8 criteria as determined by the Histiocyte Society. Treatment includes etoposide, dexamethasone, with or without intrathecal methotrexate in the presence of neurologic involvement as well as treating the underlying cause in secondary HLH. We present a case of a 23-year-old female with congenital human immunodeficiency virus (HIV) infection who presents with nonspecific signs and symptoms of cough, fever, leukopenia, and anemia, and a high-serum parvovirus B19 DNA, later diagnosed with HLH and treated with etoposide and dexamethasone. She made clinical improvements and was successfully discharged to home after 26 days of admission.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Journal of investigative medicine high impact case reports - 7(2019) vom: 12. Jan., Seite 2324709619883698 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Macauley, Precious [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6PLQ3CP4P3 |
|---|
| Anmerkungen: |
Date Completed 07.04.2020 Date Revised 08.04.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/2324709619883698 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302417281 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302417281 | ||
| 003 | DE-627 | ||
| 005 | 20231225110701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/2324709619883698 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1008.xml |
| 035 | |a (DE-627)NLM302417281 | ||
| 035 | |a (NLM)31635495 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Macauley, Precious |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hemophagocytic Lymphohistiocytosis Associated With Parvovirus B19 in a Patient With Acquired Immunodeficiency Syndrome |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2020 | ||
| 500 | |a Date Revised 08.04.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by widespread inflammation due to massive immune activation and cytokine release. It is of 2 types, primary or familial and secondary or acquired. Diagnosis is made by fulfilling 5 of 8 criteria as determined by the Histiocyte Society. Treatment includes etoposide, dexamethasone, with or without intrathecal methotrexate in the presence of neurologic involvement as well as treating the underlying cause in secondary HLH. We present a case of a 23-year-old female with congenital human immunodeficiency virus (HIV) infection who presents with nonspecific signs and symptoms of cough, fever, leukopenia, and anemia, and a high-serum parvovirus B19 DNA, later diagnosed with HLH and treated with etoposide and dexamethasone. She made clinical improvements and was successfully discharged to home after 26 days of admission | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a hemophagocytic | |
| 650 | 4 | |a lymphohistiocytosis | |
| 650 | 4 | |a parvovirus | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Abu-Hishmeh, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Dumancas, Carissa |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander-Rajan, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Piedra-Chavez, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Nada, Khaled |e verfasserin |4 aut | |
| 700 | 1 | |a Habtes, Imnett |e verfasserin |4 aut | |
| 700 | 1 | |a Popescu, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Mamorska-Dyga, Aleksandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of investigative medicine high impact case reports |d 2013 |g 7(2019) vom: 12. Jan., Seite 2324709619883698 |w (DE-627)NLM240776232 |x 2324-7096 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2019 |g day:12 |g month:01 |g pages:2324709619883698 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/2324709619883698 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2019 |b 12 |c 01 |h 2324709619883698 | ||